North America Cardiac Markers Market Outlook and Strategic Insights by 2031

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2031

North America Cardiac Markers Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Reagents and Kits, and Analyzers), Biomarker Type (Troponin, Creatine Kinase-MB, Myoglobin, B-Type Natriuretic Peptide, and Others), Indication (Congestive Heart Failure, Myocradial Infraction, Acute Coronary Syndrome, and Others), End User (Hospitals, Diagnostic Laboratories, Point-of-Care Testing Facilities, and Others), and Country (US, Canada, Mexico)

  • Report Date : May 2024
  • Report Code : TIPRE00039162
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 106

The North America cardiac markers market size is projected to reach US$ 2.87 billion by 2031 from US$ 1.17 billion in 2023. The market is expected to register a CAGR of 11.8% during 2023–2031. The use of exosome biomarkers as a new method for the diagnosis of cardiovascular diseases (CVDs) is likely to remain a key trend in the North America cardiac markers market.

North America Cardiac Markers Market Analysis

An increase in cardiovascular diseases such as heart attacks, strokes, and other heart diseases is a crucial driver for the cardiac markers market. As CVD is one of the leading causes of death in North America, there is an increased desire for early and accurate diagnosis, which can be achieved by cardiac marker testing. Cardiac markers are crucial in determining the severity of heart problems and making treatment recommendations. The development and improvement of point-of-care testing technology have significantly impacted the cardiac marker market.

North America Cardiac Markers Market Overview

Cardiac markers are most commonly used for early detection, diagnosis, and risk stratification of acute coronary syndromes so that healthcare providers can initiate relevant therapies and interventions as quickly as possible. In addition, cardiac markers are critical for monitoring patients with known cardiovascular disease, assessing treatment effectiveness, and guiding therapeutic decisions. Its widespread use in emergency departments, intensive care units, and outpatient settings demonstrates its importance in improving patient outcomes and reducing mortality rates from cardiac events.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

North America Cardiac Markers Market: Strategic Insights

north-america-cardiac-markers-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

North America Cardiac Markers Market Drivers and Opportunities

Surge in Demand for Point-of-Care Cardiac Testing Kits to Favor Market

The clinical advantages of point-of-care (POC) tests include reduced diagnostic time compared to traditional laboratory-based tests. The demand for POC test kits is surging with the increasing prevalence of CVDs, the growing geriatric population, and the ability of POC tests to provide immediate results. Several rapid and novel biomarker tests are being introduced on the back of strong research and development related to cardiovascular conditions. The POC tests can be offered as both qualitative devices and quantitative devices. Qualitative devices only indicate whether the specific biomarker is present in elevated amounts in the sample, whereas quantitative devices provide a numerical value for each biomarker. Quantitative devices are incorporated with one or more cassettes into which the sample is applied and then inserted into a benchtop analyzer to obtain the results. On the other hand, the sample is directly applied to the cassette in qualitative devices, and the results can be read directly. A surge in demand for such POC tests is bolstering the cardiac marker market growth.

Investments in Cardiovascular Medicine

With the burgeoning incidence of cardiovascular diseases, the demand for advanced diagnostics and treatments has increased significantly in North America, compelling companies to invest in their cardiology R&D capabilities. Investors are also considering forming partnerships in this discipline of medicine, which offer lucrative opportunities for market growth. A few of the recent initiatives by investors in the cardiology segment are mentioned below:

  • US Heart and Vascular, a portfolio company of Ares Management, announced a partnership with Houston-based Willowbrook Cardiovascular Associates in 2022. In 2023, the company also partnered with Orion Medical, strengthening its presence in Houston.
  • In 2023, Lee Equity Partners announced the launch of the new Cardiovascular Logistics platform in collaboration with the Cardiovascular Institute of the South (CIS), which is a large independent cardiovascular practice.
  • In Q4 of 2022, Cardiovascular Associates of America, a Webster Equity Partners portfolio company, announced a partnership with the Chicago Cardiology Institute, The Heart House of New Jersey, the Cardiovascular Institute of New England, and Southwest Cardiovascular Associates.

Such investments and partnerships by investors and companies involved in the CVD segment create lucrative opportunities for the North America cardiac marker market growth.

North America Cardiac Markers Market Report Segmentation Analysis

Key segments that contributed to the derivation of the cardiac markers market analysis are product type, biomarker type, indication, and end user.

  • Based on product type, the North America cardiac markers market is segmented into reagents and kits, and analyzers. The analyzers segment held a larger share in 2023. The reagents and kits segment is expected to register a higher CAGR during 2023–2031.
  • Based on biomarker type, the North America cardiac markers market is divided into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest market share in 2023 and is estimated to register the highest CAGR in the market during 2023–2031.
  • By indication, the market is segmented into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The congestive heart failure segment held the largest share of the market in 2023. The acute coronary syndrome segment is estimated to register the highest CAGR during 2023–2031.
  • In terms of end user, the North America cardiac markers market is divided into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The hospitals segment held the largest market share in 2023. The diagnostic laboratories segment is estimated to register the highest CAGR in the market during 2023–2031.

North America Cardiac Markers Market Share Analysis by Region

The regional scope of the North America cardiac markers market report is mainly divided into three countries: US, Canada, and Mexico.

The market growth in North America is due to the developed healthcare system and the high acceptance of cardiac markers for diagnosing and predicting diseases. The growing geriatric population needs biomarker testing for detecting conditions such as acute myocardial infarction, thereby driving demand for testing products. The presence of key players such as Quidel Corporation and Danaher Corporation is another factor contributing to the growth of the North America cardiac markers market. The World Health Organization (WHO) states that ~77 million adults over the age of 18 have type 2 diabetes, including 25 million prediabetes, which increases the possibility of CVDs and puts additional pressure on the healthcare system. Furthermore, well-planned business strategies by market players in this region to develop innovative cardiac biomarker tests are expected to contribute to the market growth in this region.

North America Cardiac Markers Market Regional Insights

The regional trends and factors influencing the North America Cardiac Markers Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses North America Cardiac Markers Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

north-america-cardiac-markers-market-global-geography
  • Get the Regional Specific Data for North America Cardiac Markers Market

North America Cardiac Markers Market Report Scope

Report Attribute Details
Market size in 2023 US$ 1.17 Billion
Market Size by 2031 US$ 2.87 Billion
Global CAGR (2023 - 2031) 11.8%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product Type
  • Reagents and Kits
  • Analyzers
By Biomarker Type
  • Troponin
  • Creatine Kinase-MB
  • Myoglobin
  • B-Type Natriuretic Peptide
By Indication
  • Congestive Heart Failure
  • Myocradial Infraction
  • Acute Coronary Syndrome
By End User
  • Hospitals
  • Diagnostic Laboratories
  • Point-of-Care Testing Facilities
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott Laboratories
  • F.Hoffmann-La Roche
  • Thermo Fischer Scientific Inc
  • Beckman Coulter Inc
  • Bio-Rad Laboratories Inc
  • Creative Diagnostics
  • Diazyme Laboratories Inc
  • Biomerieux SA
  • Hytest Ltd
  • QuidelOrtho Corp.

  • North America Cardiac Markers Market Players Density: Understanding Its Impact on Business Dynamics

    The North America Cardiac Markers Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the North America Cardiac Markers Market are:

    1. Abbott Laboratories
    2. F.Hoffmann-La Roche
    3. Thermo Fischer Scientific Inc
    4. Beckman Coulter Inc
    5. Bio-Rad Laboratories Inc
    6. Creative Diagnostics

    Disclaimer: The companies listed above are not ranked in any particular order.


    north-america-cardiac-markers-market-cagr

    • Get the North America Cardiac Markers Market top key players overview

    North America Cardiac Markers Market News and Recent Developments

    The North America cardiac markers market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the North America cardiac markers market are listed below:

    • Hytest Ltd expanded into North America with a subsidiary, Hytest North America. The company will launch local operations to better serve customers and meet growing demands. With a local team in the US, the company will strive to enhance accessibility to products and services, ensuring a smoother experience for valued customers in North America. (Source: Hytest Ltd, Press Release, 2024)
    • Hytest Ltd announced the launch of the latest troponin product, the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex. (Source: Hytest Ltd, Press Release, 2023)
    • Abbott announced that the US Food and Drug Administration (FDA) approved an expanded indication for the company's CardioMEMS HF System to support caring for more people with heart failure. With the expanded indication, an additional 1.2 million US patients can now benefit from advanced monitoring with the CardioMEMS sensor, which marks a significant increase over the current addressable population. The sensor provides an early warning system, enabling doctors to protect against worsening heart failure. (Source: Abbott Laboratories, Press Release, 2022)

    North America Cardiac Markers Market Report Coverage and Deliverables

    The “North America Cardiac Markers Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

    • North America cardiac markers market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • North America cardiac markers market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • North America cardiac markers market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America cardiac markers market
    • Detailed company profiles

    Frequently Asked Questions

    What is cardiac marker?

    Cardiac markers are the tests used for the diagnosis and risk assessment of patients with chest pain and suspected acute coronary syndrome (ACS) and for management and prognosis in patients with acute heart failure, pulmonary embolism, and other diseases.

    Who are the major players in the cardiac marker market?

    The cardiac marker market majorly consists of the players such Abbott Laboratories, F.Hoffmann-La Roche, Thermo Fischer Scientific Inc, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Creative Diagnostics, Diazyme Laboratories Inc, Biomerieux SA, Hytest Ltd, and QuidelOrtho Corp.

    Which country is dominated the cardiac marker market?

    The US has dominated the cardiac marker market owing to increasing product development and growing government support for enhancing heart treatment. In addition, the growing prevalence of heart diseases and the risk involved have led to the market growth. All these factors are expected to fuel the US cardiac marker market by 2031.

    Which biomarker type segment is dominating the cardiac marker market?

    By biomarker type, the market is segmented into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest share of the market in 2023.

    Which product type segment is dominating the cardiac marker market?

    Based on product type, the North America cardiac marker market is divided into reagents and kits, and analyzers. The analyzers segment held the largest market share in 2023.

    Which indication segment is dominating the cardiac marker market?

    In terms of indication, the market is segmented into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The congestive heart failure segment held the largest market share in 2023.

    Mrinal Kerhalkar
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    user

    I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

    DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
    user

    The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

    Yukihiko Adachi CEO, Deep Blue, LLC.

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Strategic Planning
    • Investment Justification
    • Identifying Emerging Markets
    • Enhancing Marketing Strategies
    • Boosting Operational Efficiency
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients

    The List of Companies - North America Cardiac Markers Market

    1. Abbott Laboratories
    2. Beckman Coulter Inc
    3. Creative Diagnostics
    4. Bio-Rad Laboratories Inc
    5. Diazyme Laboratories Inc
    6. bioMerieux SA
    7. HyTest Ltd
    8. QuidelOrtho Corp
    9. Thermo Fisher Scientific Inc
    10. F. Hoffmann-La Roche Ltd
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo